Blocking 5-HT2B receptors abolishes psilocybin’s efficacy in the rat forced swim test
Journal of Psychopharmacology June 23, 2026 Lenka Seillier, Alexandre Seillier, Morgan A. Zvolska et al.
BACKGROUND: Major depressive disorder is one of the most debilitating psychiatric disorders worldwide. First-line treatments such as selective serotonin reuptake inhibitors have significant limitations, including delayed onset of therapeutic effects and treatment resistance in about 30% of patients. Increasing evidence suggests that acute administration of serotonergic psychedelics, such as...